Hexapradol
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:22, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 04:22, 22 June 2020 by DMacks (talk | contribs) (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB))
Clinical data | |
---|---|
Other names | α-butyl-β-hydroxy-β-phenylamphetamine α-pentyl-β-hydroxy-β-phenyl-2-phenethylamine β-phenyl-2-phenylheptanolamine |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H25NO |
Molar mass | 283.415 g·mol−1 |
3D model (JSmol) | |
| |
|
Hexapradol (INN) is a psychostimulant drug which was never marketed.[1]
Synthesis
GB 805511 , (1958); CA, 53, 12249
See also
References
- ^ Dictionary of Pharmacological Agents Volume 2. CRC Press. p. 1023. ISBN 978-0-412-46630-4. Retrieved 26 April 2012.
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |